Mutational spectrum
There are more than 140 different mutations in SLC12A3. 1, 2, 4, 8, 9, 11, [14] [15] [16] These mutations include missense-, nonsense-, frame-shift-, and splice-site mutations. In addition, deletions of (part) the gene have been identified.
Only a few mutations in CLCNKB have been identified; patients with CLCNKB mutations have a highly variable phenotype, ranging from an antenatal onset of Bartter syndrome on one side of the spectrum, to a phenotype closely resembling Gitelman syndrome at the other side. Therefore, there is an indication to screen the CLCNKB gene in patients with the Gitelman phenotype who do not have mutations in the SLC12A3 gene.
Analytical methods
Direct automated sequencing for mutations.
MLPA for deletions.
Analytical validation
Internal validation through analysis of known mutations in anonymized samples.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) 1 in 40 000.
1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting
Comment: a prenatal test is technically feasible, but as yet has never been asked for because of the good prognosis in the majority of patients. The tests are primarily blood and urine tests. So, the only burden is the drawing of a blood sample, which is also necessary for the genetic test.
TEST CHARACTERISTICS

How is the cost effectiveness of alternative diagnostic methods to be judged?
Genetic testing is at the moment more expensive than biochemistry, but this may change in future. 
Will disease management be influenced by the result of a genetic test?
(Continued)
The long-term prognosis of Gitelman syndrome appears to be excellent, with the restriction that the molecular counterpart of the disease has only been identified in 1996 and that long-term clinical studies are lacking. The potential severity of Gitelman syndrome has been emphasized, with a significant reduction of the quality of life and fatigue able to hamper some patients in their daily activities. Manifestations such as early onset (before age 6 years), growth retardation, invalidating chondrocalcinosis, tetany, rhabdomyolysis, seizures and ventricular arrythmia have been described in a limited number of cases. 7 Progression to renal insufficiency is extremely rare in GS. As yet, only one patient who developed chronic renal insufficiency and subsequent progression to end-stage renal disease has been reported.
Management (please describe)
Most asymptomatic patients with GS remain untreated and are monitored ambulatory (generally by nephrologists) with low 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) Yes, for the confirmation of the diagnosis and for genetic counselling.
